76,979 Shares in McKesson Corporation $MCK Purchased by Bristol Gate Capital Partners Inc.

Bristol Gate Capital Partners Inc. acquired a new stake in McKesson Corporation (NYSE:MCK) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 76,979 shares of the company’s stock, valued at approximately $58,166,000. McKesson makes up about 4.0% of Bristol Gate Capital Partners Inc.’s holdings, making the stock its 20th largest position.

A number of other large investors also recently bought and sold shares of the company. University of Texas Texas AM Investment Management Co. bought a new stake in McKesson during the fourth quarter valued at $25,000. Swiss RE Ltd. bought a new position in shares of McKesson in the 4th quarter worth about $26,000. Delos Wealth Advisors LLC bought a new position in shares of McKesson in the 2nd quarter worth about $27,000. State of Wyoming acquired a new position in shares of McKesson in the 2nd quarter valued at about $29,000. Finally, Kingdom Financial Group LLC. acquired a new position in shares of McKesson in the 4th quarter valued at about $33,000. Institutional investors own 85.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on MCK shares. UBS Group increased their price objective on shares of McKesson from $1,050.00 to $1,080.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Barclays lifted their target price on McKesson from $925.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Wednesday, August 19th. Weiss Ratings lowered McKesson from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, July 7th. Royal Bank Of Canada assumed coverage on McKesson in a report on Wednesday, August 19th. They issued a “sector perform” rating and a $845.00 price target on the stock. Finally, Robert W. Baird set a $1,015.00 price objective on McKesson in a research report on Thursday, August 6th. Fourteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $973.44.

McKesson News Roundup

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson agreed to acquire Precision Medicine Group for approximately $2.25 billion. The transaction would add clinical research, consulting and biopharma commercialization capabilities to McKesson’s oncology-focused business, broadening its exposure to higher-growth healthcare services. Reuters article about McKesson’s Precision Medicine acquisition
• Positive Sentiment: McKesson raised its fiscal 2027 earnings outlook as oncology demand, GLP-1 volumes and specialty pharmaceutical distribution accelerate. The higher guidance reinforces expectations for double-digit earnings growth and supports investor confidence in the company’s growth strategy. McKesson FY2027 guidance article
• Positive Sentiment: Short interest fell 33% to about 2.42 million shares as of August 14, representing roughly 2.1% of shares outstanding and 2.2 days of average trading volume. The decline suggests reduced bearish positioning and may provide additional support for the stock.
• Neutral Sentiment: Healthcare stocks broadly advanced late Tuesday, giving McKesson a favorable sector backdrop. However, sector-wide gains do not necessarily reflect company-specific fundamentals. Healthcare sector update
• Negative Sentiment: Analysts caution that McKesson’s premium valuation leaves less room for execution setbacks. Drug-pricing pressure, potential policy changes and cash-flow demands associated with expansion and acquisitions remain risks to the investment thesis. McKesson valuation analysis

Insiders Place Their Bets

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 133 shares of the business’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $764.00, for a total transaction of $101,612.00. Following the completion of the transaction, the chief accounting officer owned 632 shares in the company, valued at approximately $482,848. The trade was a 17.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Brian S. Tyler sold 8,463 shares of the business’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $793.56, for a total value of $6,715,898.28. Following the transaction, the chief executive officer owned 5,919 shares of the company’s stock, valued at $4,697,081.64. This trade represents a 58.84% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 23,111 shares of company stock valued at $18,011,274. 0.06% of the stock is owned by corporate insiders.

McKesson Stock Up 3.5%

MCK stock opened at $904.31 on Wednesday. The stock has a market cap of $105.43 billion, a PE ratio of 24.20, a price-to-earnings-growth ratio of 1.72 and a beta of 0.30. The firm’s 50-day simple moving average is $825.22 and its 200 day simple moving average is $844.60. McKesson Corporation has a fifty-two week low of $673.38 and a fifty-two week high of $999.00.

McKesson (NYSE:MCK) last posted its earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.56 by $0.37. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The firm had revenue of $105.38 billion during the quarter, compared to analyst estimates of $103.88 billion. During the same period in the previous year, the business posted $8.26 EPS. McKesson’s revenue was up 7.7% on a year-over-year basis. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Equities analysts forecast that McKesson Corporation will post 44.65 EPS for the current fiscal year.

McKesson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Tuesday, September 1st will be given a dividend of $0.94 per share. This is a boost from McKesson’s previous quarterly dividend of $0.82. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Tuesday, September 1st. McKesson’s payout ratio is presently 8.78%.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.